摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4’-(三氟甲基)联苯-4-甲醛 | 90035-34-0

中文名称
4’-(三氟甲基)联苯-4-甲醛
中文别名
4'-三氟甲基二苯基-4-甲醛;三氟甲基二苯基-4-甲醛;4-三氟甲基联苯-4-甲醛
英文名称
4-(4-trifluoromethylphenyl)benzaldehyde
英文别名
4'-(trifluoromethyl)-[1,1'-biphenyl]-4-carbaldehyde;4'-(trifluoromethyl)biphenyl-4-carbaldehyde;4′-(trifluoromethyl)-[1,1′-biphenyl]-4-carbaldehyde;4'-(trifluoromethyl)-biphenyl-4-carboxaldehyde;4’-(trifluoromethyl)-[1,1′-biphenyl]-4-carbaldehyde;4-(p-trifluoromethylphenyl)benzaldehyde,;4'-Trifluoromethyl-biphenyl-4-carbaldehyde;4-[4-(trifluoromethyl)phenyl]benzaldehyde
4’-(三氟甲基)联苯-4-甲醛化学式
CAS
90035-34-0
化学式
C14H9F3O
mdl
MFCD01862519
分子量
250.22
InChiKey
HIMSXOOFWOOYFK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    70-72°C
  • 沸点:
    319.7±42.0 °C(Predicted)
  • 密度:
    1.251±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    18
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.071
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 海关编码:
    2913000090
  • 危险性防范说明:
    P280,P305+P351+P338
  • 危险性描述:
    H302
  • 储存条件:
    室温

SDS

SDS:3cbad66eb1e8ce4392e4cfca12288a7f
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4’-Trifluoromethylbiphenyl-4-carbaldehyde
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4’-Trifluoromethylbiphenyl-4-carbaldehyde
CAS number: 90035-34-0

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C14H9F3O
Molecular weight: 250.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

简介

4'-三氟甲基二苯基-4-甲醛可作为医药合成中间体,可通过溴苯甲醛与对三氟甲基苯硼酸反应制备,进而用于合成化合物1-(4'-(三氟甲基)-[1,1'-联苯]-4-基)丁-1-醇。

制备

将4.625g(25mmol)对溴苯甲醛、9.495g(50mmol)对三氟甲基苯硼酸、1.445g(1.25mmol)四(三苯基膦)钯、13.8g(100mmol)碳酸钾、100mL乙二醇二甲醚和15mL水混合,氮气抽排气三次后,在110°C反应24小时。反应结束后,使用二氯甲烷萃取,有机相用水及饱和食盐水洗涤,无水硫酸镁干燥,通过柱层析分离得到产物(3.878g),产率约为62%。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

点击查看最新优质反应信息

文献信息

  • Production methods of alpha, alpha, alpha-trifluoromethylphenyl-substituted benzoic acid and intermediate therefor
    申请人:——
    公开号:US20010020110A1
    公开(公告)日:2001-09-06
    The present invention relates to a production method of compound [V] useful as an intermediate for medicaments and agrochemicals. The method includes reacting compound [III] with hexamethylenetetramine under heating to give compound [IV], and oxidizing the obtained compound [IV] with a halous acid salt or a ruthenium compound. According to the present invention, moreover, an organometallic compound having a tolyl group and compound [I] are cross-coupled in the presence of a catalyst to give compound [II] useful as an intermediate for medicaments and agrochemicals. The compound [II] is halogenated to give compound [III]. 1 wherein X is halogen atom.
    本发明涉及一种用作医药和农药中间体的化合物[V]的生产方法。该方法包括在加热下将化合物[III]与六甲基四胺反应以得到化合物[IV],以及用卤素酸盐或钌化合物氧化所得到的化合物[IV]。根据本发明,另外,在催化剂存在下,将具有甲苯基的有机金属化合物与化合物[I]进行交叉偶联以得到用作医药和农药中间体的化合物[II]。化合物[II]被卤素化以得到化合物[III]。 1 其中X是卤素原子。
  • 18-Crown-6 promoting Pd/C-catalyzed cross-coupling reaction of aryl bromides and arylboronic acids in aqueous media
    作者:Wenyi Chu、Xinmin Li、Yanjun Hou、Hua Wang、Hongyu Li、Xiaobin Yuan、Zhizhong Sun
    DOI:10.1002/aoc.2891
    日期:2012.9
    Pd/C‐catalyzed Suzuki–Miyaura cross‐coupling between aryl bromides and arylboronic acids in 50% methanol aqueous solution proceeded smoothly in the presence of 18‐crown‐6. Various aryl bromides bearing electron‐withdrawing groups and electron‐donating groups coupled with arylboronic acid in high yields. In addition, the catalyst could be recycled five times without loss of activity. Copyright © 2012
    在18冠冕6存在下,钯/碳催化的Suzuki-Miyaura在50%甲醇水溶液中的芳基溴化物和芳基硼​​酸之间的交叉偶联反应顺利进行。各种带有吸电子基团和给电子基团的芳基溴化物与芳基硼酸偶联,收率很高。另外,该催化剂可以循环使用五次而不会损失活性。版权所有©2012 John Wiley&Sons,Ltd.
  • 噁唑烷酮类化合物、其制备方法、用途及其药 物组合物
    申请人:中国科学院上海药物研究所
    公开号:CN111825695B
    公开(公告)日:2022-04-12
    本发明涉及用作Lp‑PLA2共价抑制剂的噁唑烷酮类化合物及其药物组合物,所述噁唑烷酮类化合物的结构如通式I所示,R1,R2和R3的定义如说明书和权利要求书所示。本发明的通式I化合物其立体异构体或其药学上可以接受的盐,可用作Lp‑PLA2共价抑制剂,预防和/或治疗和/或改善与Lp‑PLA2酶活性有关的疾病。同时,本发明的通式I化合物其立体异构体或其药学上可以接受的盐,可用作Lp‑PLA2特异性的分子探针。
  • BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL
    申请人:Kuo Gee-Hong
    公开号:US20070244094A1
    公开(公告)日:2007-10-18
    The invention is directed to compounds of Formula (I) useful as PPAR agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, diabetes, nephropathy, neuropathy, retinopathy, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cataract, cardiovascular diseases, Metabolic X Syndrome, hyper-LDL-cholesterolemia, dyslipidemia (including hypertriglyceridemia, hypercholesterolemia, mixed hyperlipidemia, and hypo-HDL-cholesterolemia), atherosclerosis, obesity, and other disorders related to lipid metabolism and energy homeostasis complications thereof, using compounds of the invention are also described.
    该发明涉及一种化合物,其化学式为(I),可用作PPAR激动剂。还描述了使用该发明的化合物治疗糖尿病、肾病、神经病、视网膜病变、多囊卵巢综合征、高血压、缺血、中风、肠易激综合征、炎症、白内障、心血管疾病、代谢X综合征、高LDL胆固醇血症、血脂异常(包括高甘油三酯血症、高胆固醇血症、混合性高脂血症和低HDL胆固醇血症)、动脉粥样硬化、肥胖以及其他与脂质代谢和能量稳态并发症相关的疾病的药物组合物和治疗方法。
  • The Discovery of Novel ACA Derivatives as Specific TRPM2 Inhibitors that Reduce Ischemic Injury Both In Vitro and In Vivo
    作者:Han Zhang、Peilin Yu、Hongwei Lin、Zefang Jin、Siqi Zhao、Yi Zhang、Qingxia Xu、Hongwei Jin、Zhenming Liu、Wei Yang、Liangren Zhang
    DOI:10.1021/acs.jmedchem.0c02129
    日期:2021.4.8
    melastatin 2 (TRPM2) channel is associated with ischemia/reperfusion injury, inflammation, cancer, and neurodegenerative diseases. However, the limit of specific inhibitors impedes the development of TRPM2-targeted therapeutic agents. To discover more potent and selective TRPM2 inhibitors, 59 N-(p-amylcinnamoyl) anthranilic acid (ACA) derivatives were synthesized and evaluated using calcium imaging and electrophysiology
    瞬时受体电位褪黑素 2 (TRPM2) 通道与缺血/再灌注损伤、炎症、癌症和神经退行性疾病相关。然而,特异性抑制剂的限制阻碍了TRPM2靶向治疗药物的开发。为了发现更有效和选择性的 TRPM2 抑制剂,我们合成了 59 N -(对戊基肉桂酰基)邻氨基苯甲酸 (ACA) 衍生物,并使用钙成像和电生理学方法进行了评估。系统的结构-活性关系研究发现一些有效的化合物能够以亚微摩尔半最大抑制浓度值抑制 TRPM2 通道。其中,优选的化合物A23对TRPM8和TRPV1通道以及磷脂酶A2表现出TRPM2选择性,并在体外表现出神经保护活性。经过药代动力学研究, A23在体内短暂性大脑中动脉闭塞模型中进行了进一步评估,该模型显着减少了脑梗塞。这些数据表明, A23可能作为 TRPM2 相关研究的有用工具,以及开发缺血性损伤治疗药物的先导化合物。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐